• Raphael Pharmaceutical entered a 12-month managed AI transformation partnership with AIcreatesAI, effective July 30, 2026.
• Annual managed-services fee set at USD 180,000, paid in USD 15,000 monthly installments, with invoices deferrable when funds are unavailable.
• Deferred amounts become payable upon financing, investment, commercial revenue, or other resources; share settlement possible with AIcreatesAI consent.
• Agreement also contemplates a company-branded digital token platform, subject to board approval; AIcreatesAI to receive 2% of net profits.
• Either party can terminate for uncured material breach after 15 days’ notice.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Raphael Pharmaceutical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-096113), on September 01, 2026, and is solely responsible for the information contained therein.